S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)

• Alan Anderson,
• Fuad El Rassi,
• Michael R. Debaun,
• Modupe Idowu,
• Julie Kanter,
• Soheir Adam,
• Susanna Curtis,
• Darla Liles,
• Biree Andemariam,
• Morgan L. Mclemore,
• Robert Sheppard Nickel,
• Poornima Ramadas,
• Jincy Paulose,
• Dram Laine,
• Mahmudul Khan,
• Deepika Darbari,
• Arthur L. Burnett

Affiliations

Alan Anderson

1 Prisma Health-Upstate Comprehensive SCD Program, University of South Carolina School of Medicine, Greenville, SC, United States

Fuad El Rassi

2 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States

Michael R. Debaun

3 Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University School of Medicine, Nashville, TN, United States

Modupe Idowu

4 UT Physicians Comprehensive Sickle Cell Center, University of Texas, Houston, TX, United States

Julie Kanter

5 UAB Sickle Cell Clinic, University of Alabama, Birmingham, AL, United States

Soheir Adam

6 Duke Adult Comprehensive Sickle Cell Center, Duke University, Durham, NC, United States

Susanna Curtis

7 Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, United States

Darla Liles

8 Brody School of Medicine, East Carolina University, Greenville, NC, United States

Biree Andemariam

9 New England Sickle Cell Institute at the University of Connecticut, Farmington, CT, United States

Morgan L. Mclemore

2 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States

Robert Sheppard Nickel

10 Comprehensive Sickle Cell Disease Program, Children’s National Hospital, Washington, DC, United States

Poornima Ramadas

11 Feist-Weiller Cancer Center, LSU Health Shreveport, Shreveport, LA, United States

Jincy Paulose

12 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States

Dram Laine

12 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States

Mahmudul Khan

12 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States

Deepika Darbari

10 Comprehensive Sickle Cell Disease Program, Children’s National Hospital, Washington, DC, United States

Arthur L. Burnett

13 Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, United States